Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Search
C3-binding polypeptide
C3-binding polypeptide
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
equine asthma
Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
Chronic kidney disease in cats
Detect and manage chronic kidney disease and high blood pressure in cats
Breakthrough introduction innovation pet parasiticides
In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
Helping smallholder farmers after Covid-19
In Ghana, we are helping smallholder farmers overcome hardship caused by the pandemic.
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Xochimilco
The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
Pets
Pets
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
Livestock
Livestock
Breakthrough Designation granted in US and China
SPEVIGO® granted Breakthrough Therapy Designation in the U.S. for the prevention of generalized pustular psoriasis flares
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Partnering with Boehringer Ingelheim: BIO International 2024
Learn about innovation and partnering with Boehringer Ingelheim human pharma, animal health and biopharma contract manufacturing at BIO International 2024
More Green
More Green
Cooperation with The Defeat-NCD Partnership
Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Mexico rabies free dog vaccination campaigns
Mexico: a champion in the fight against rabies. The first country in the world to be declared free from dog-transmitted rabies.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Poultry
Poultry
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.